Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. The Company's product candidate, batoclimab, is a fully human, monoclonal antibody targeting the neonatal fragment crystallizable receptor. Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for Myasthenia Gravis (MG), Thyroid Eye Disease (TED) and Warm Autoimmune Hemolytic Anemia (WAIHA). The Company is conducting a phase I drug-drug interaction (DDI) study in healthy volunteers to characterize the pharmacokinetic (PK) profile of atorvastatin with and without the coadministration of batoclimab.
Buy US stocks in Australia starting with IMVT. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in IMVT
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.